AEON’s Value Tanks As It Closes $20m Offering Amid Botox Biosimilar Aspirations
Firm Met With FDA Last Year On Botox Candidate; AEON Confident On Alignment
AEON Biopharma says it is planning for a biosimilar biological product development type 2 meeting in 2025 for its proposed biosimilar to the world-famous Botox brand, after raising much-needed capital to keep it afloat in 2025.
